Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD)

Trial Profile

Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tirzepatide (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Acronyms TREASURE-CKD
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 20 Apr 2025 Planned End Date changed from 1 Feb 2026 to 1 Oct 2026.
  • 20 Apr 2025 Planned primary completion date changed from 1 Jan 2026 to 1 Sep 2026.
  • 03 Dec 2024 Planned End Date changed from 26 Feb 2026 to 1 Feb 2026.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top